Anupam Rasayan Projects FY27 Revenue Of ₹4,800–5,000 Crore With 23% Margin

Market snapshot: Anupam Rasayan management highlighted expected strength in the second half of the financial year following the consolidation of recent acquisitions. The company projects FY27 revenue between ₹4,800 crore and ₹5,000 crore alongside an operating margin target of 23% (as stated in the source alert; not independently verified).

Data Snapshot

• Anupam Rasayan reported Q2 FY27 basic EPS of ₹4.39 and H1 FY27 basic EPS of ₹7.79 in its updated regulatory submission.
• Completed acquisition of a 48.2% controlling stake in Bliss GVS Pharma to establish an integrated specialty platform.
• Standalone revenue reached ₹1,676 crore for FY26 across custom synthesis operations.

What's Changed

• Consolidation of strategic acquisitions (including Bliss GVS Pharma) completed, expanding downstream integration.
• H2 operational execution expected to drive overall revenue toward the ₹4,800–5,000 crore range (as stated in the source alert; not independently verified).

Key Takeaways

• Anupam Rasayan management expects strong H2 trajectory post-acquisition consolidation.
• FY27 revenue guided between ₹4,800 crore and ₹5,000 crore with a 23% margin target (as stated in the source alert; not independently verified).
• Q2 FY27 basic EPS reported at ₹4.39 following regulatory disclosures.

SAHI Perspective

Anupam Rasayan's progress on asset consolidation positions the chemical manufacturer to capture value across extended pharmaceutical and specialty product lines. If the projected 23% margin profile is achieved (as stated in the source alert; not independently verified), operational leverage in H2 could enhance medium-term earnings resilience.

Market Implications

The specialty chemical sector is seeing enhanced value capture through strategic forward integration. Broader asset portfolios offer increased revenue stability across commercial supply agreements.

Trading Signals

Market Bias: Bullish

Management commentary points to a strong H2 operational outlook and FY27 revenue targets of ₹4,800–5,000 crore (as stated in the source alert; not independently verified), backed by grounded Q2 FY27 basic EPS of ₹4.39.

Overweight: Specialty Chemicals, CDMO & Pharma Intermediates

Trigger Factors:

• Realization of synergies from consolidated business units
• Quarterly margin trajectory toward the 23% target
• Volume growth in core custom synthesis contracts

Time Horizon: Medium-term (3-12 months)

Industry Context

Indian custom synthesis and specialty chemical players are shifting toward higher-value pharmaceutical intermediates and finished formulations to mitigate raw material price volatility.

Key Risks to Watch

• Integration complexity across newly acquired business units
• Global channel inventory fluctuations impacting export order cycles
• Raw material cost volatility affecting target operating margins

Recent Developments

Anupam Rasayan completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma in September 2026. On November 6, 2026, the company submitted its Q2 FY27 unaudited results reporting basic EPS of ₹4.39.

Closing Insight

Execution during H2 FY27 will be key in evaluating whether Anupam Rasayan can turn its strategic acquisitions into sustained margin expansion.

High Performance Trading with SAHI.